Pharmaceutical

In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.

Investors need to pay close attention to BDX stock based on the movements in the options market lately.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Mounjaro generated $8.66 billion in sales in the first quarter.

Eli Lilly's next-generation weight-loss drug, Retatrutide, could hit the shelves soon. Though the treatment has yet to attain FDA approval, demand is already so heavy that consumers are going to the black market to buy it.

BDX beats second-quarter fiscal 2026 earnings and revenue estimates, driven by broad segment strength and improved profitability.

Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has plummeted more than 30%.

Becton Dickinson (BDX) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $3.35 per share a year ago.

Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the ​market to millions more patients and help counter pricing pressure.

Becton Dickinson raised its annual profit forecast on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, and appointed Vitor ​Roque as its chief financial officer.

FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7.

Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1 FRANKLIN LAKES, N.J., May 7, 2026 /PRNews

Eli Lilly's Zepbound is already generating billions of dollars in revenue, making it the clear leader in a rapidly expanding market. Lilly's ability to produce and deliver creates a hurdle that smaller competitors can't easily overcome.

Is Pfizer a yield trap? No way.

Eli Lilly And Co (NYSE:LLY) has capitalized on last week's impressive first-quarter earnings report.

Pfizer (PFE) chief executive Albert Bourla has signaled a possible shift in tone around US vaccine policy, praising President Donald Trump's latest nominee to l

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

The S&P 500 has gained 5% this year, but there's the risk of a crash later in the year.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

Eli Lilly ​said on ‌Wednesday it would ​commit ​an additional $4.5 billion ⁠investment across ​two ​of its three sites in ​Indiana, ​bringing the company's ‌total ⁠capital expansion commitments in the ​state ​since ⁠2020 to ​more ​than $21 ⁠billion.

Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturing facility LEBANON, Ind., May 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

South Korea Pharmaceutical Filtration Market Trends: Biopharma Growth, Sterile Processing & Forecast to 2033 vocal.media

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

DUBLIN, Ohio, May 5, 2026  /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.

Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a “very credible scientist.

Just because a dividend stock has suffered a significant stumble doesn't mean the setback is permanent. It doesn't even mean its dividend is in jeopardy.

Novartis to close German manufacturing site, cutting 220 jobs Fierce Pharma

Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript

Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.

Pfizer (PFE) delivered a stronger-than-expected first quarter as demand for several older blockbusters helped cushion the continued drop in Covid-related revenu

Gaining An Edge In GLP-1 Production Bioprocess Online

Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted revenue of $14.5 billion for the quarter ended March 31, up 5% from a year earlier and ahead of analyst estimate

This month's trio included a dividend aristocrat.

Pfizer reported Q1 revenues of $14.5bn, with adjusted EPS down 18% and a 6.54% dividend yield. PFE faces major patent expirations on key drugs like Eliquis and Vyndaqel, pressuring future revenues despite recent M&A and pipeline efforts. Recent acquisitions, including Seagen, have yet to deliver material commercial upside, while high debt limits further M&A flexibility, although the Metsera deal i

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street.

Pfizer Inc  (NYSE:PFE) stock is down 1.1% to trade at $26.03 at last check.

Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Beyond analysts' top-and-bottom-line estimates for Becton Dickinson (BDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago.

Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocks This analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE. Bitcoin Rallies $1,415 Higher - Here's Why. 58 minutes ago Live Bitcoin is up $1,415... Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.

The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.